Bromodomain and Extra-Terminal Inhibitors Pipeline Analysis - Patent, Designation, Collaboration and Developments
The study analyzed that the BET inhibitors pipeline comprised 38 drug candidates in different stages of development.
Explore report sample at: https://www.psmarketresearch.com/market-analysis/bet-inhibitors-pipeline-analysis/report-sample
As per the findings of the research, most of the BET inhibitor pipeline drug candidates are being developed to be administered by oral route.
In BET inhibitors, IC50 value is measured as the concentration of drug at which 50% of the target is inhibited. IC50 is a pharmacokinetic measure; the lower the IC50 of drug candidate, the lesser the desired effect, and the less likelihood of the drug to have some off-target effect. Kd is known as dissociation constant of drug. It measures the rate of dissociation of the drug and its binding affinity. Birabresib (MK8628), a BET inhibitor by Merck & Co., has IC50 value of 100nM.
Browse report at: https://www.psmarketresearch.com/market-analysis/bet-inhibitors-pipeline-analysis
Some of the key players developing BET inhibitors are Resverlogix Corp., GlaxoSmithKline plc, Bristol-Myers Squibb Company, and others.
About P&S Intelligence
P&S Intelligence, a brand of P&S Market Research, is a provider of market research and consulting services catering to the market information needs of burgeoning industries across the world. Providing the plinth of market intelligence, P&S as an enterprising research and consulting company, believes in providing thorough landscape analyses on the ever-changing market scenario, to empower companies to make informed decisions and base their business strategies with astuteness.
Contact:
P&S Intelligence
Toll-free: +1-888-778-7886 (USA/Canada)
International: +1-347-960-6455
Email: enquiry@psmarketresearch.com
